{"id":"dtg-based-arv-regimen-with-abc","safety":{"commonSideEffects":[{"rate":"14%","effect":"Nausea"},{"rate":"12%","effect":"Diarrhea"},{"rate":"10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL191973","moleculeType":"Small molecule","molecularWeight":"437.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DTG (dolutegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into host DNA.","oneSentence":"Inhibits HIV-1 integrase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:11:23.584Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT03327740","phase":"","title":"PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-09-30","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DTG based ARV regimen with ABC","genericName":"DTG based ARV regimen with ABC","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits HIV-1 integrase Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}